<DOC>
	<DOCNO>NCT01168856</DOCNO>
	<brief_summary>This observational long-term follow-up study assess persistence direct act antiviral ( DAA ) resistant mutation durability sustain virological response patient chronic hepatitis C participate Roche DAA treatment protocol . Up 5 scheduled monitoring visit blood sample observational period 36 month .</brief_summary>
	<brief_title>An Observational Study Long-Term Persistence Resistant Mutations And Durability Sustained Virological Response Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral ( DAA ) - Containing Regimens</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>adult patient , &gt; /=18 year age chronic hepatitis C participation Roche DAA treatment protocol CHC infection DAAassociated resistant mutation persist last evaluation donor protocol , partial viral response viral load rebound RO5024048 treatment , sustain virological response &gt; /= 20 week last dose study medication donor study For patient participate DAA resistance monitoring : Initiation treatment participation donor protocol evidence crossresistance donor protocol DAA For patient participate DAA SVR durability : Treatment antiHVC therapy since establish SVR donor study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>